An Overview of Respiratory Syncytial Virus

1. ZhouH, ThompsonWW, ViboudCG, RingholzCM, ChengPY, et al. (2012) Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008. Clin Infect Dis 54 : 1427–1436.

2. HallCB, WeinbergGA, IwaneMK, BlumkinAK, EdwardsKM, et al. (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360 : 588–598.

3. ThompsonWW, ShayDK, WeintraubE, BrammerL, CoxN, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 : 179–186.

4. NairH, NokesDJ, GessnerBD, DheraniM, MadhiSA, et al. (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375 : 1545–1555.

5. MahadeviaPJ, MasaquelAS, PolakMJ, WeinerLB (2012) Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. J Med Econ 15 : 987–996.

6. WelliverTP, GarofaloRP, HosakoteY, HintzKH, AvendanoL, et al. (2007) Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 195 : 1126–1136.

7. MooreML, ChiMH, LuongoC, LukacsNW, PolosukhinVV, et al. (2009) A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol 83 : 4185–4194.

8. Boyoglu-BarnumS, GastonKA, ToddSO, BoyogluC, ChirkovaT, et al. (2013) A respiratory syncytial virus (RSV) anti-G protein F(ab′)2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected Balb/c mice. J Virol 87 : 10955–10967.

9. LeeS, StokesKL, CurrierMG, SakamotoK, LukacsNW, et al. (2012) Vaccine-Elicited CD8+ T Cells Protect against Respiratory Syncytial Virus Strain A2-Line19F-Induced Pathogenesis in BALB/c Mice. J Virol 86 : 13016–13024.

10. StokesKL, ChiMH, SakamotoK, NewcombDC, CurrierMG, et al. (2011) Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol 85 : 5782–5793.

11. OhumaEO, OkiroEA, OcholaR, SandeCJ, CanePA, et al. (2012) The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease. Am J Epidemiol 176 : 794–802.

12. WrightPF, GruberWC, PetersM, ReedG, ZhuY, et al. (2002) Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. J Infect Dis 185 : 1011–1018.

13. LukensMV, van de PolAC, CoenjaertsFE, JansenNJ, KampVM, et al. (2010) A systemic neutrophil response precedes robust CD8(+) T-cell activation during natural respiratory syncytial virus infection in infants. J Virol 84 : 2374–2383.

14. SandeCJ, MutungaMN, MedleyGF, CanePA, NokesDJ (2013) Group -⁠ and genotype-specific neutralizing antibody responses against respiratory syncytial virus in infants and young children with severe pneumonia. J Infect Dis 207 : 489–492.

15. McLellanJS, ChenM, LeungS, GraepelKW, DuX, et al. (2013) Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody. Science 340 : 1113–1117.

16. CortiD, BianchiS, VanzettaF, MinolaA, PerezL, et al. (2013) Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501 : 439–443.

17. MagroM, MasV, ChappellK, VazquezM, CanoO, et al. (2012) Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. PNAS 109 : 3089–3094.

18. MunirS, HillyerP, Le NouenC, BuchholzUJ, RabinRL, et al. (2011) Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response. PLoS Pathog 7: e1001336.

19. LingZ, TranKC, TengMN (2009) Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I. J Virol 83 : 3734–3742.

20. RamaswamyM, ShiL, VargaSM, BarikS, BehlkeMA, et al. (2006) Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology 344 : 328–339.

21. BukreyevA, YangL, CollinsPL (2012) The secreted G protein of human respiratory syncytial virus (RSV) antagonizes antibody-mediated restriction of replication involving macrophages and complement. J Virol 86 : 10880–10884.

22. GrahamBS (2011) Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 239 : 149–166.

23. KarronRA, WrightPF, BelsheRB, ThumarB, CaseyR, et al. (2005) Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 191 : 1093–1104.

24. HotardAL, ShaikhFY, LeeS, YanD, TengMN, et al. (2012) A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 434 : 129–136.

25. El SaleebyCM, BushAJ, HarrisonLM, AitkenJA, DevincenzoJP (2011) Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis 204 : 996–1002.